Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

November 3, 2017: By Joan McKenna


Allergan told analysts Nov. 1 that it is taking several steps to prepare for loss of patent exclusivity for Restasis in 2018, even as net sales of its dry eye treatment increased 2.9 percent in Q3-2017 year over year.

Allergan CEO Brent Saunders said the move followed a recent US district court decision that invalidated four of Restasis’ patents. The company has appealed the decision.

Dublin-based Allergan has taken impairment charges of $3.2 billion related to Restasis and $164.0 million related to other dry eye assets obtained in its acquisition of legacy Allergan.

In addition, the company is making plans to reduce costs, while protecting long-term growth drivers, as it prepares for possible scenarios, including a Restasis generic launching Jan. 1, 2018, or one launching in mid-2018. The FDA currently has not approved a generic version.

Saunders said those cost reductions will be implemented rapidly as soon as officials complete their planning. Still, the company intends to increase its dividend and pay down nearly $4 billion in debt in Q1-2018.

Allergan’s net revenues in Q3-2017 totaled $4.03 billion, an 11 percent increase over the same quarter in 2016.

Officials noted that the company is committed to eye care, which is a $2 billion annual business without Restasis.

Other ophthalmic products that performed well in the third quarter included Ozurdex, an implant for diabetic macular edema and other retinal conditions. Net revenues increased 17.7 percent in the US to $24.6 million and 12 percent outside the US to $50.2 million, due to increasing demand.

Restasis’ net revenues in the third quarter totaled $366.8 million. Full-year revenues are expected to total about $1.4 billion.

Asked about competition from compounding pharmacies, Saunders said Allergan would watch the situation closely, ensuring that compounders are not allowed to find an alternative path to launching drugs without the full oversight and review that the FDA has for medicines.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023